Text: : Agent of Horizons can't be blocked this turn.
Text: Heroic — Whenever you cast a spell that targets Akroan Crusader, put a 1/1 red Soldier creature token with haste onto the battlefield.
Text: Whenever Akroan Hoplite attacks, it gets +X/+0 until end of turn, where X is the number of attacking creatures you control.
Text: Anger of the Gods deals 3 damage to each creature. If a creature dealt damage this way would die this turn, exile it instead.
Text: Counter target artifact or enchantment spell.
Text: Heroic — Whenever you cast a spell that targets Anthousa, Setessan Hero, up to three target lands you control each become 2/2 Warrior creatures until end of turn. They're still lands.
Text: Heroic — Whenever you cast a spell that targets Arena Athlete, target creature an opponent controls can't block this turn.
Text: Heroic — Whenever you cast a spell that targets Artisan of Forms, you may have Artisan of Forms become a copy of target creature and gain this ability.
Text: +2: Exile the top three cards of target opponent's library.
Text: : Regenerate Asphodel Wanderer.
Text: Whenever a creature you control deals combat damage to a player, you may draw a card.
Text: Target creature gets +2/+0 until end of turn. Regenerate it. You lose 2 life.
Text: Boulderfall deals 5 damage divided as you choose among any number of target creatures and/or players.
Text: Attacking creatures you control have deathtouch.
Text: Heroic — Whenever you cast a spell that targets Centaur Battlemaster, put three +1/+1 counters on Centaur Battlemaster.
Text: When Chronicler of Heroes enters the battlefield, draw a card if you control a creature with a +1/+1 counter on it.
Text: Reveal the top five cards of your library. You may put a creature or enchantment card from among them into your hand. Put the rest into your graveyard.
Text: Up to two target creatures each get +1/+0 and gain first strike until end of turn.
Text: , Sacrifice Crackling Triton: Crackling Triton deals 2 damage to target creature or player.
Text: Exile X target creatures. For each creature exiled this way, its controller puts a 2/2 green Boar creature token onto the battlefield.
Text: Up to two target creatures each get +1/+1 and gain lifelink until end of turn.
Text: Destroy target black creature.
Text: Up to two target creatures each get +2/+2 until end of turn.
Text: Daxos of Meletis can't be blocked by creatures with power 3 or greater.
Text: Deathbellow Raider attacks each turn if able.
Text: Prevent all combat damage that would be dealt to players this turn.
Text: Destroy target artifact or enchantment. Destructive Revelry deals 2 damage to that permanent's controller.
Text: +1: Put three 1/1 white Soldier creature tokens onto the battlefield.
Text: : Tap target creature with power 3 or less.
Text: Exile target artifact or enchantment.
Text: Heroic — Whenever you cast a spell that targets Favored Hoplite, put a +1/+1 counter on Favored Hoplite and prevent all damage that would be dealt to it this turn.
Text: Whenever Firedrinker Satyr is dealt damage, it deals that much damage to you.
Text: , , Sacrifice Flamecast Wheel: Flamecast Wheel deals 3 damage to target creature.
Text: Whenever you scry, Flamespeaker Adept gets +2/+0 and gains first strike until end of turn.
Text: Equipped creature has flying and haste.
Text: Whenever another creature dies, tap Fleshmad Steed.
Text: Exile target white permanent.
, , Sacrifice a land: Put a 3/3 colorless Golem enchantment artifact creature token onto the battlefield.
Text: Destroy target creature or planeswalker.
Text: Target green creature you control gets +2/+2 until end of turn. It fights target green creature an opponent controls.
Text: Minotaur creatures you control have haste.
Whenever a Minotaur you control attacks, it gets +2/+0 until end of turn.
Text: Heroic — Whenever you cast a spell that targets Labyrinth Champion, Labyrinth Champion deals 2 damage to target creature or player.
Text: When Lagonna-Band Elder enters the battlefield, if you control an enchantment, you gain 3 life.
Text: Target creature gets -4/-4 until end of turn.
Text: Exile target creature with power 2 or less. Its controller gains 4 life.
Text: When Leonin Snarecaster enters the battlefield, you may tap target creature.
Text: Lightning Strike deals 3 damage to target creature or player.
Text: : Loathsome Catoblepas must be blocked this turn if able.
Text: Return up to two target creature cards from your graveyard to your hand.
Whenever Medomai the Ageless deals combat damage to a player, take an extra turn after this one.
Medomai the Ageless can't attack during extra turns.
Text: , : The controller of target instant or sorcery spell copies it. That player may choose new targets for the copy.
Text: Mistcutter Hydra can't be countered.
Text: Nemesis of Mortals costs less to cast for each creature card in your graveyard.
Whenever enchanted creature attacks, put a +1/+1 counter on it. Then if it has three or more +1/+1 counters on it, sacrifice Ordeal of Purphoros.
When you sacrifice Ordeal of Purphoros, it deals 3 damage to target creature or player.
Text: Destroy target Mountain. Peak Eruption deals 3 damage to that land's controller.
Text: Heroic — Whenever you cast a spell that targets Phalanx Leader, put a +1/+1 counter on each creature you control.
Text: Pharika's Cure deals 2 damage to target creature and you gain 2 life.
Text: When Pharika's Mender enters the battlefield, you may return target creature or enchantment card from your graveyard to your hand.
Text: , Sacrifice Priest of Iroas: Destroy target enchantment.
Discard a card: Prognostic Sphinx gains hexproof until end of turn. Tap it.
Text: Untap all creatures and lands you control during each other player's untap step.
Text: Equipped creature can't be blocked except by Walls.
Text: Target opponent reveals his or her hand. You choose a nonland card from that player's graveyard or hand and exile it. You may cast that card for as long as it remains exiled, and you may spend mana as though it were mana of any color to cast that spell.
Text: : Each player exiles the top card of his or her library face down.
, , Sacrifice Pyxis of Pandemonium: Each player turns face up all cards he or she owns exiled with Pyxis of Pandemonium, then puts all permanent cards among them onto the battlefield.
Text: Destroy target enchantment. You gain 3 life.
: Reaper of the Wilds gains deathtouch until end of turn.
: Reaper of the Wilds gains hexproof until end of turn.
Text: As an additional cost to cast Rescue from the Underworld, sacrifice a creature.
Text: , Sacrifice Satyr Hedonist: Add to your mana pool.
Text: : Target creature must be blocked this turn if able.
Text: Target creature gets +2/+2 until end of turn. Untap that creature.
Text: : Each opponent loses 1 life. You gain life equal to the life lost this way.
Text: Sealock Monster can't attack unless defending player controls an Island.
Text: Heroic — Whenever you cast a spell that targets Setessan Battle Priest, you gain 2 life.
: Target creature an opponent controls attacks this turn if able.
, : Attacking creatures get -1/-1 until end of turn.
Text: Shredding Winds deals 7 damage to target creature with flying.
Text: Destroy target creature. Its controller loses 2 life.
, : Destroy target creature that dealt damage to you this turn.
Enchanted creature gets +2/+2 and has first strike.
Text: Heroic — Whenever you cast a spell that targets Staunch-Hearted Warrior, put two +1/+1 counters on Staunch-Hearted Warrior.
Text: Reveal the top five cards of your library and separate them into two piles. An opponent chooses one of those piles. Put that pile into your hand and the other into your graveyard.
Text: Counter target enchantment, instant, or sorcery spell. Its controller puts a 2/2 blue Bird creature token with flying onto the battlefield.
Text: Temple of Abandon enters the battlefield tapped.
Text: Temple of Deceit enters the battlefield tapped.
Text: Temple of Mystery enters the battlefield tapped.
Text: Temple of Silence enters the battlefield tapped.
Text: Temple of Triumph enters the battlefield tapped.
Text: Draw three cards. Target player puts the top three cards of his or her library into his or her graveyard.
Whenever Thassa's Emissary or enchanted creature deals combat damage to a player, draw a card.
Text: Each Human creature you control has " , : This creature deals 1 damage to target creature or player."
Text: Tormented Hero enters the battlefield tapped.
Text: , Sacrifice Traveler's Amulet: Search your library for a basic land card, reveal it, and put it into your hand. Then shuffle your library.
Text: , : Put a fate counter on another target creature.
, : Exile target creature that has a fate counter on it, then return it to the battlefield under its owner's control.
, : Exile target creature that has a fate counter on it. Its controller draws two cards.
Text: Heroic — Whenever you cast a spell that targets Triton Fortune Hunter, draw a card.
Text: Up to two target creatures each get +0/+3 until end of turn. Untap those creatures. At this turn's next end of combat, tap each creature that was blocked by one of those creatures this turn and it doesn't untap during its controller's next untap step.
Text: , Sacrifice another creature: Tymaret, the Murder King deals 2 damage to target player.
Text: Underworld Cerberus can't be blocked except by three or more creatures.
Text: Until end of turn, up to two target creatures you control each gain "Whenever this creature deals combat damage to a player, draw a card."
Text: Heroic — Whenever you cast a spell that targets Wavecrash Triton, tap target creature an opponent controls. That creature doesn't untap during its controller's next untap step.
Text: Creatures you control have lifelink.
Text: When Wild Celebrants enters the battlefield, you may destroy target artifact.
Text: +1: Add X mana in any combination of and/or to your mana pool, where X is the number of creatures you control.


text:
MDedge.com
Acute Coronary Syndromes
Arryhthmias
CAD & Atherosclerosis
Lipid Disorders
Peripheral Vascular Disorders
Interventional Cardiology & Surgery
E-cig use reverses progress in reducing tobacco use in teens
Heidi Splete
FROM CDC VITAL SIGNS REPORT
A significant increase during 2017-2018 in e-cigarette use among U.S. youths has erased recent progress in reducing overall tobacco product use in this age group, a study from the Centers for Disease Control and Prevention has found.
Courtesy CDC
Nearly 5 million middle school and high school students in the United States, approximately 27% of high school students and 7% of middle school students, used tobacco products, including e-cigarettes, in 2018, according to study findings.
E-cigarettes are driving the trend. About 4 million high school students in the United States reported using any tobacco product in the last 30 days, and 3 million of them reported using e-cigarettes, according to a Vital Signs document published by the CDC on Feb. 11 in its Morbidity and Mortality Weekly Report.*
In addition, many high school students who use e-cigarettes use them often; 28% reported using the products at least 20 times in the past 28 days, up from 20% in 2017.
"Any use of any tobacco product is unsafe for teens," Anne Schuchat, MD, principal deputy director of the CDC, said in a teleconference to present the findings. Nicotine is highly addictive and can harm brain development in youth, including capacity for learning, memory, and attention, she said.
The rise in e-cigarette use corresponds with the rise in marketing and availability of e-cigarette devices such as JUUL, which dispense nicotine via liquid refill pods available in flavors including strawberry and cotton candy, said Brian King, MPH, PhD, deputy director for research translation at the CDC's Office on Smoking and Health.
"The advertising will lead a horse to water, the flavors will make them drink, and the nicotine will keep them coming back for more," said Dr. King.
AHA report highlights CVD burden, declines in smoking, sleep importance
Quizzes and Polls
Subscribe to Cardiology News

redpajama_set_name: RedPajamaCommonCrawl


text:
Facility & Rentals
Four Guyz in Dinner Jackets®
Now in Technicolor*
Friday, February 25, 7:30 pm
You may be doing a double take when you read this because The Four Guyz in Dinner Jackets® performed this great show a few years back at SMPAC. Now, they'll be performing it again on Friday, February 25. They were planning to premiere their new show, Call Us Old Fashioned: The Supper Club Tour on this date, but due to extenuating circumstances, they are postponing the release of the new show. So, back by popular demand, experience the sounds and sights of the Golden Age of Entertainment. In Now in Technicolor, The Four Guyz in Dinner Jackets® revive musical memories from the 50s, 60s and 70s radio and TV. This high-octane show is delivered in the style expected from The Four Guyz along with their band, including charming choreography and comic banter. Whether you are a fan of classic doo-wop, pop, rock or bubble-gum, these Guyz will please the lover of time-honored Americana.
Ticket pricing: Adult $35-$45, Senior $32-$42, Student $15-$20
*If you previously purchased tickets for Call Us Old Fashioned: The Supper Club Tour and would like a refund, contact the box office at (414) 766-4049 no later than February 15.
We are at full capacity seating, with no seats left intentionally empty. We'll continue to monitor and reevaluate the latest COVID-19 information and update our policies as needed. Click here for the latest health safety guidelines and sign up to receive notifications below.
A concert for all ages.
Official Artist Website
Fri, Feb 25th, 2022 at 7:30 pm
Premium $45 + $2/ticket fee
Mid-level $40 + $2/ticket fee
Side seats $35 + $2/ticket fee
Senior (60+)
Student (6+ - college)
South Milwaukee Performing Arts Center
Rachel Sorce, Executive Director
(414) 766-5048 | rsorce@sdsm.k12.wi.us
Open by phone M-Th, 10-3. Closed when school is closed. Open for walk-up sales one hour before most events.
Email: pacboxoffice@sdsm.k12.wi.us
We only send out a few emails each month. We don't sell your information.
© South Milwaukee Performing Arts Center | Ticketing System provided by Arts People


text:
Happy Quaildays!
Happy Yule/Christmas/Kwanza/New Year!
Illustration: Laura Bramble
Dear fledglings,
If you follow our blog of The Real—which we hope you do!—you've probably already seen Laura Bramble's terrific paper cut-out style illustration of a quail hugging a Christmas tree (um, above). Well, we love it SO much that we just had to share it here on the About blog. We also wanted to take another chance to wish you a fabulous holiday season. Happy Yule! Merry Christmas! Happy Kwanza! Happy New Year!
Feathery hugs,
The Quail Bell Crew
P.S. Please don't forget to check out The Children of Jackson Ward/the Quail Bell Scholarship for Creative Promise!
Welcome to our staff blog, where you can learn more about The Quail Bell Crew.
Christine Stoddard conceived the idea for Quail Bell in late 2009 after writing a children's story by the same name, and launched the website as a college blog in 2010. In June 2013, Christine and former art director Kristen Rebelo officially launched Quail Bell Magazine as a global web magazine. Read our editorial mission statement to learn more.
The QB Crew
Christine Stoddard, Founding Editor
Art, media, and language have enchanted Christine Stoddard since the days of her early upbringing in Arlington, VA. While still a mere fairy flutter from D.C., Christine dove into creative activities, hoping that her artistic talents would distract her teachers from learning of her mathematical inability. Luckily, her plan worked. Her non-math skills have been recognized by regional and national organizations. In October 2011, Style Weekly Magazine named her one of the "Top 40 Under 40" in Richmond, VA, while she was still a VCUarts student. Christine currently lives and works in her native Virginia. Email her at: cstoddard@quailbell.com.
Gretchen Gales,
Though Gretchen first dedicated her life to being a veterinarian and a best-selling writer on the side, her lack of technical abilities helped guide her towards a literary and art career. Gretchen has published work in Ms., Bustle, The Establishment, and over 30 other publications. She also has been interviewed in Dear English Major and Her Campus. More of her work can be found at writinggales.wordpress.com.


text:
Thirty six schemes jostled their way to the final London Awards, with the judges spoilt for choice. Hazel Rounding sees two sides of the city in the list. Click on the images for more
Hazel Rounding: Around 20 years ago, London was the choice for young entrepreneurs. Pledge yourself to the hardships of the capital and say goodbye to the regions. This message projected itself socially and professionally: 'You can dress however you wish, London schools of architecture are the best, and Londoners create great buildings.'
A deep recession drove some talent to the regions where fresh European investment was being pumped into forgotten urban areas. The result was arguably a more robust and consistent attitude to what makes a great built environment across the UK. Also, faster travel and digital communications led to a more holistic view of the capital and the regions – within a one hour local commute or two hours by high-speed rail networks, and all within the return of an email.
It is no longer just the elite country house owner who now manages to travel to the city from outposts in the far flung 'home counties', it is pretty much any one of country's population. You are free to live close to a London borough high street or a city in the Midlands or the North.
However, the impact is that, while the regions are closer to Greater London, the nucleus of central London is even further removed from the rest of the country. This is a global centre which throws up amazing opportunities through large scale investment. But does this make it an exhilarating place to work, with endless opportunity, or is there a risk in its power?
What will it become as a place to live the everyday? How do we address the social risks of such a split in financial dynamics? Are we – the workforce – the ones who can ensure the creation and continuity of London as our capital with global standing? How can we prevent an even greater schism between central and Greater London than that which has historically existed between London and the regions? Hazel Rounding is a director at Shedkm, Liverpool and London
Houses and housing
Tin House Credit: Luke Caufield
Curzon Bloomsbury Credit: Helene Binet
The Bath House Children's Community Centre
Regent High School Credit: Dennis Gilbert
RIBA East Awards 2016
RIBA South West Awards 2016
RIBA West Midlands Awards 2016


text:
The 1992–93 UEFA Champions League preliminary round was the qualifying round for the 1992–93 UEFA Champions League, and featured eight teams. It began on 19 August with the first legs and ended on 2 September 1992 with the second legs. The four winners advanced to the first round, joining 28 other teams.

Times are CEST (UTC+2), as listed by UEFA.

Format
Each tie was played over two legs, with each team playing one leg at home. The team that scored more goals on aggregate over the two legs advanced to the next round. If the aggregate score was level, the away goals rule was applied, i.e. the team that scored more goals away from home over the two legs advanced. If away goals were also equal, then extra time was played. The away goals rule would be again applied after extra time, i.e. if there were goals scored during extra time and the aggregate score was still level, the visiting team advanced by virtue of more away goals scored. If no goals were scored during extra time, the tie was decided by penalty shoot-out.

Draw
The draw for the preliminary round was held on 15 July 1992 in Geneva, Switzerland.

Summary

The first legs were played on 19 August, and the second legs on 2 September 1992.

|}

Matches

Tavriya Simferopol won 2–1 on aggregate.

Maccabi Tel Aviv won 3–1 on aggregate.

Skonto won 6–1 on aggregate.

Olimpija Ljubljana won 5–0 on aggregate.

References

External links

Preliminary round
UEFA Champions League qualifying rounds
August 1992 sports events in Europe
September 1992 sports events in Europe

redpajama_set_name: RedPajamaWikipedia


text:
Biden's Radical Budget Nominee Faces Bipartisan Opposition
Neera Tanden, President Joe Biden's nominee for Director of the Office of Management and Budget (OMB). (Anna Moneymaker/The New York Times via AP, Pool, File)
(Headline USA) President Joe Biden's nomination of Neera Tanden to lead the White House Office of Management and Budget was thrown further into doubt on Monday as moderate Republican Sen. Susan Collins of Maine said she would vote against confirming Tanden.
Associated Press reports that Utah Republican Sen. Mitt Romney will also oppose Joe Biden's nomination of Neera Tanden as director of the White House Office of Management and Budget.
On Friday, Sen. Joe Manchin of West Virginia became the first Democrat lawmaker to oppose Tanden's confirmation.
But the White House called her, without evidence, "an accomplished policy expert who would be an excellent Budget Director," and Biden said he was sticking with her.
Collins, though, said Monday that Tanden has "neither the experience nor the temperament to lead this critical agency," which heads efforts to ensure an administration's priorities are reflected in legislation and regulations.
Collins blamed Tanden's past actions and said they "demonstrated exactly the kind of animosity that President Biden has pledged to transcend."
During her confirmation hearings, Tanden apologized for spending years attacking top Republicans on social media.
Tanden is a former adviser to Hillary Clinton and served as president of the leftist Center for American Progress.
With the Senate evenly divided between 50 Republicans and 50 Democrats, and with Vice President Kamala Harris serving as a tiebreaking vote, losing Manchin means Tanden would need support from at least one Republican to win confirmation.
Tanden really can't afford to lose another Democrat vote.
The Senate Budget Committee is scheduled to vote on Tanden's nomination this week.
It's the first real test that Biden has faced on a nomination, with most of his picks for Cabinet positions sailing through the chamber with bipartisan support.
Collins criticized Tanden for deleting tweets in the days before her nomination was announced and said that "raises concerns about her commitment to transparency."
She said Congress "has to be able to trust the OMB director to make countless decisions in an impartial manner, carrying out the letter of the law and congressional intent."
"The OMB needs steady, experienced, responsive leadership," Collins said in a statement. "I will vote against confirming Ms. Tanden."
Manchin said bipartisanship is "more important than ever" as the nation faces many crises and suggested Tanden was overtly partisan.
"I believe her overtly partisan statements will have a toxic and detrimental impact on the important working relationship between members of Congress and the next director of the Office of Management and Budget," Manchin said in a statement.
Tanden had also disparaged some Democrats on social media, most notably Sen. Bernie Sanders, the independent from Vermont.
Biden, asked Friday whether he would pull Tanden's nomination, said he wouldn't.
"I think we are going to find the votes and get her confirmed," Biden said.
The White House said on Monday she has "lived experience having benefitted from a number of federal programs as a kid."
"Looking ahead to the committee votes this week and continuing to work toward her confirmation," White House press secretary Jen Psaki tweeted.
Previous articleFlorida vs. California: Lockdown Showdown
Next articleUN to Rich Nations: Don't Order More Vaccines for Yourselves


text:
Food & Agriculture Innovators
Agriculture >
Technology Podcasts
@RealMikeBetts
https://foodaginnovators.com/
mike@foodaginnovators.com
7: Less Sugar, More Protein Using Mushroom Technology - Alan Hahn of MycoTechnology
Alan Hahn is the co-founder and CEO of MycoTechnology, a food ingredient technology company. The company creates fungi-based powders using a proprietary fermentation process. Their product line today includes a taste modulating powder called ClearTaste and a protein powder called PureTaste. They've also shown the ability to remove toxins in foods and are working through "probably a lifetime of ideas" in using fungi to improve food. The big wins today though are that their ClearTaste...
6: Making Healthier Sugars Tagatose and Allulose - Ed Rogers of Bonumose
Ed Rogers is the co-founder and CEO of Bonumose, a food ingredient technology company. The company's patented process was invented by co-founder Dr. Dan Wichelecki and utilizes combinations of natural enzymes to convert plant-based raw materials into low cost, "good sugars" tagatose and allulose, that aim to mimic sucrose (or table sugar) and come with a host of claimed beneficial properties. Get the full show notes here. If you like the show, you can subscribe to it on any podcast app....
5: Climate Change Fighting Fungi and Empowering Smallholder Farmers - Rusty Rodriguez of Adaptive Symbiotic Technologies
Dr. Rusty Rodriguez is the CEO of Adaptive Symbiotic Technologies (AST), an ag biotech company that has developed microbial solutions that enable plants to battle climate and environmental stress, increasing crop quality and yields. These stressors include drought, temperature stress and salty soils, to name a few. The company is selling to both commodity crop farmers and smallholder "monsoon" farmers in the absolute worst of drought conditions in India. These farmers have been able to...
4: Ranching in the Ocean with Phil Cruver of Catalina Sea Ranch, a shellfish aquaculture company
Phil Cruver is the Founder and CEO of Catalina Sea Ranch (CSR), which owns the first offshore aquaculture facility in U.S. federal waters. This was a fascinating conversation as Phil tells the story of how he had to essentially build a new industry in the U.S. We cover a lot of ground in this interview. And when it comes to raising funding for a startup with grand ambitions like CSR, he has some wisdom from the 6 companies he's started on how to allocate equity in the early stages of a...
3: Predicting Crop Yields, Satellite Imagery and Machine Learning with David Potere of TellusLabs
David Potere is Co-founder and CEO of TellusLabs, a company that combines decades of satellite imagery with machine learning to predict crop yields and help its customers, which range from farmer to hedge fund manager. Get the full show notes at here. If you like the show, you can subscribe to it on any podcast app. Support us by leaving a review on iTunes, Apple Podcasts, or Stitcher Radio. Reviews really help the show grow and allow other people find the show, it only takes a...
2: Investing in Brazilian AgTech with Francisco Jardim of SP Ventures
Francisco Jardim is Co-founder and Managing Director of venture capital firm, SP Ventures. In the interview we discuss how his firm is capitalizing on the opportunity of agriculture technology investing in Brazil. Get the full show notes here. If you like the show, you can subscribe to it on any podcast app, drop us a review or send us a message / subscribe to the newsletter at foodaginnovators.com. In this interview, we cover: accelerator program Pulse
1: Farming Flies and Business Building in the Sustainability Revolution with Jason Drew of AgriProtein
Jason Drew is the Co-founder and CEO of AgriProtein based in Cape Town, South Africa. In the interview we go back to the early years and career of Jason, how he got started on his path to farming flies, the business of AgriProtein that's raised nearly $30 million dollars of venture capital, the art of building your company into the "Sustainability Revolution", recent growth plans announced to scale farming of insects globally, and more. Get the full show notes here. If you like the show,...


Falling, flying, making love to a stranger, being naked in public – we've all woken up, wondering 'Why did I dream that?' In this lively and thorough guide to the world of night time fantasies, nightmares, and visions, dream specialist Gayle Delaney helps readers interpret, understand, and direct their dreaming. Drawing together dream history and the latest techniques, she lets readers in on the most fascinating new thinking about dream interpretation and explains how the ancients used and understood dreams. Delaney shows readers how to live their dreams and direct what they dream about and when. She also offers a complete resource guide of 'dream-y' books and tapes, study groups, and web sites. From a fascinating survey of dream history – Aristotle to Jung – to the stunning new ways business, arts, science, and health care use dreamwork today, Delaney presents an enchanting – and practical – dream 'bible' sure to find a place on the shelf of every curious, fascinated dreamer.


Some of us extinguish all possibilities before even understanding what we are leaving behind. Flourish in faith and leave behind that which is not yours to receive.
You can reason out what you think you deserve. But God decides what gifts He bestows upon you even before you get to that point in time.
But somehow we stifle what is suppose to be ours before the opportunity is presented.
Do you really think you know better than God?
Being honest, I don't think it's a matter of knowing we're better. It's more a thought process that we think we are doing what He desires for us. We just miss the mark…too many times.
Why is all of our concern wrapped up in what others see in us, rather than what God sees.
The practice of how you see yourself through God's eyes is hard to achieve. In fact, it's not about achieving it, but focusing on it daily.
The K.I.S.S. ~ Flourish in faith!
Show up when you don't want to. Give up when you are directed. Look up as your Father knows best.
God wants you to step out into the great unknown and trust that He's got you! All of you!! He will equip you with exactly what you need when you need it.
His layers of love and grace go much deeper than what we can see.
Rise and shine into the valley of the unknown and walk with the full confidence that God conquered this path.
God's goodness is beyond our comprehension here on earth, but He's given us the opportunity to experience it beyond measure.
Expect the unexpected. Rise and shine with a heart ready for greatness and a mind willing to seek.
What you thought wasn't possible is now within your reach.
Grasp quickly to what God places before you. Don't waver or put it off. Great is His faithfulness.
CHALLENGE: Where will you accept the challenge to be stretched?
Thank you, Mark for listening! I pray your week is filled with Heavenly challenges! He's going to stretch your heart and your mind. What an honor to meet you! You're a blessing! Looking forward to seeing God's continued handiwork in your life. Aloha!


Remember MPF on Give STL Day on Thursday, May 11, 2017 » Grow Native!
Jefferson City, MO (April 25, 2017) — The Missouri Prairie Foundation, named earlier this year the Conservation Federation of Missouri's Conservation Organization of 2016, will participate in Give St. Louis, a day of on-line giving on Thursday, May 11, 2017, organized by the St. Louis Community Foundation.
Those wishing to make a tax-deductible contribution to the Missouri Prairie Foundation through Give St. Louis may do so beginning at 12:00 a.m. May 11, 2017 at www.givestlday.org/MissouriPrairieFoundation. The minimum donation is $10.
The Missouri Prairie Foundation, a statewide organization, was named the Conservation Organization of the Year on March 10, 2017 in recognition of its many accomplishments in 2016, including outstanding stewardship of rare prairie habitat, dedication of its 20th prairie acquisition, robust educational programming, and other achievements.
The Missouri Prairie Foundation protects and restores original prairie and other native grasslands through land acquisition, prairie management, education, and research. The Foundation owns and manages 21 properties totaling more than 3,300 acres that are open to the public to enjoy. Once covering at least 15 million acres in Missouri, the remaining estimated 70,000 scattered acres of prairie in Missouri are home to a stunning diversity of plants and animals, including more species of native pollinators than any other habitat in the state.
The Foundation's outreach and education program includes continuous publication of the Missouri Prairie Journal since 1979, its annual Prairie BioBlitz, and many other activities. The Foundation also runs the 17-year-old Grow Native! program and the Missouri Invasive Plant Species Task Force.
To learn more about the Missouri Prairie Foundation's work, and to register for the Foundation's free 8th Annual Prairie BioBlitz on June 10 and 11 and other events, visit www.moprairie.org or www.grownative.org.


text:
Goverment to Introduce Anti Begging Laws
Thread starter alltheway
alltheway
Just saw this on the RTE website
RTÉ News: New laws to crack down on begging
Not sure how i feel about this and by that i mean, how many of those people begging want to be begging?
Are we just trying to cover up a problem with poverty?
KungFugazi
Bertie is for the chop so.
mccafferty cat
Cracking down on begging, at the beginning of a crippling recession and record unemployment....
Great to see FF moving to solve the REAL problems we have.......
Don't we already have a Vagrancy Act? What's wrong with this? It may have been introduced in Dickensian times but the powers it grants can't really be added to in any meaningful way
"It was never about a personal agenda or vendetta, or any political motivation"
David Cochrane
Libertas employee
FutureTaoiseach
greatdearleader.blogspot.com
This is most welcome. There is a woman on the streets of Wexford town for 20 years, and I have been informed by someone who knows her that she owns a home. In that context, she is just being a nuisance, and is behaving in an undignified and nuisancical matter. I also believe that illegal-immigrants found to be begging should be summarily deported. I am also firmly of the belief that most beggars and 'homeless' people are in fact not homeless in the strict definition of that term. Many are mentally-ill, and belong in an institution.
"4° It shall be for the House or Houses concerned to determine...the appropriate balance between the rights of persons and the public interest..."
scsa1981
Its about time. I am sick and tired of seeing gypsy Roma scum shove babies in my face and demand money. Dublin city centre is absolutely infested with these vermin. Imagine putting your child through that? I also see small Roma boys put out on the streets to beg. Why arent their parents arrested for this? It's getting more like Calcutta by the day. The top of Grace Park Road in Dublin 9where the sign for the airport is also very bad with Roma gangs of 3 or 4 surrounding cars demanding money.
Reactions: FutureTaoiseach
PhoenixIreland
I thought this was already illegal? I've seen cops move on beggers before.
If you want to help homeless people donate to a homeless charity, handing them money either gets them drug or drink money or give is to someone whos having you on and is not actually homeless.
because the fathers send the mothers out to do it, and the mothers either send the kids or use the kids as bait.
"we will permanently end waiting lists in our hospitals within two years": Fianna Fail 2002 Manefesto
"41,000 patients on hospital waiting lists": RTE News (2007)
20000miles
www.irishliberty.wordpress.com
Oh the irony...
Ludwig von Mises Institute ¦ Irish Liberty Forum
FutureTaoiseach said:
Yeah.......
Personally though, I think the problem of begging on our streets is being caused by the unelected European elites who just won't take No for an answer. These proposals on begging are an affront to democracy, and the notion that they can be put before the people again is being disrespectful to democracy.
Furthermore, the Charter of Fundamental rights promotes begging in all its forms, and condemns children as young as 3 to head out on the streets. Only when this pro-begging Charter is removed from Lisbon, can we vote Yes
Defeated Romanticist
I thought the law against begging was striken down as unconstitutional by Justice De Valera a year or two ago...
This is ofcourse welcome. The partisan quibbling of the bleeding heart(!) blueshirts to one side. Far from being the ast resort of the poverty striken, some of the most troubling begging is by children and women of which little of the money stays with them.
Liquidate labour, liquidate stocks, liquidate the farmers, liquidate real estate.
It is about flaming time too!! They should also allow drivers to run down any beggar on the roads - traffic lights, roundabouts etc.
mccafferty cat said:
Defeated Romanticist said:
It was, there's a quick bit about it here. It'll be interesting to see how this new bill gets round that judgement.
Nothing will motivate the lazy / apathetic / Americanised / west-British types to embrace their culture and the Irish language.
Can you not just reply to a thread without having ago with someone?
Reactions: CookieMonster
alltheway said:
Especially a group that hasn't existed for 60 years.
I'm having the same reaction. While beggers are a pain in the hoop, I don't believe all of them are there because they want to be. They should be doing more to combat the causes underlying the need to beg before the start criminalising beggers. Making them criminals as well as thking away their access to cash (for whatever reason) isn't going to help solve the problem.
Happiness is a dry martini and a good woman … or a bad woman.
Anorakphobia
Does this new law extend to FF and/or their disgraced former leader going out begging for billions off shady hedge funds to bail them out of their own incompetence?
martel said:
Its petty begging that is usually more of an annoyance than anything else. What is the government going to do about big time beggars/thieving scumbags? Answer: absolutely nothing,in this jokeshop country big time beggars/thieving scumbags tend to get honorary doctorates and awards. Its a topsy turvy world.
Bertie Ahern presented with award for contribution to security in Ireland - National News, Frontpage - Independent.ie
I presume you are joking?
"......... we must sometimes listen to those who, consumed with zeal, have scant judgment or balance. To such ones the modern world is nothing but betrayal and ruin.........We feel bound to disagree with these prophets of doom who are forever forecasting calamity -- as though the world's end were imminent."
corelli said:
He's taking the pis out of FT's stump speech.
zakalwe1
i thought they got plum state appointed jobs (cus they were me mates)!
hang on, that for the patrons of beggers, the beggers themselves become taoiseach!
I liberate minds with my music. That's more important than liberating a few people from apartheid or whatever. - Kanye West
I don't find them that much of a nuisance to be bringing in new laws and wasting Gardai time.
I think they are one of the reasons why Obama's campaign was so successfull. I heard, that he turned to one, one day and asked him "what do we need ?".
Yes, I am bored today.


text:
Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance 2019 Galafold Revenue Expected to Nearly Double – with Guidance of $160M-$180M Pompe Phase 3 PROPEL Study Expected to Complete Enrollment and Additional Phase 2 Pompe Data in 2019 Additional 2-Year Data from Phase 1/2 CLN6 Batten Disease Clinical Study Anticipated Mid-Year 2019 Ongoing Phase 1/2 CLN3 Batten Disease Study Expected to Complete Enrollment in 2019 Preclinical Proof of Concept for Fabry and Pompe Gene Therapy Programs Expected in 2019 Strong Balance Sheet with $500M+ Cash CRANBURY, NJ, January 7, 2019 – Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today provided unaudited preliminary Galafold revenue for the full-year 2018 and introduced its full-year 2019 strategic outlook and financial guidance. During 2018 Amicus met or exceeded all five key strategic priorities: • More than doubled global revenue for Galafold (migalastat). Revenue grew from $36.9 million in full-year 2017 to approximately $91 million (preliminary and unaudited) in full-year 2018, exceeding the high end of the full-year 2018 guidance range of $80 million to $90 million. • Successfully secured approvals for migalastat in the U.S. and Japan, with strong initial adoption. As of December 31, 2018, 149 patients in the U.S. have been prescribed Galafold since the August launch. • Achieved clinical, manufacturing and regulatory milestones to advance AT-GAA toward global regulatory submissions and approvals. Highlights included positive 12- and 18-month data from the ongoing Phase 1/2 clinical study, manufacturing scale up (1000L), and first patient dosed in the PROPEL pivotal study. • Pipeline expanded to include 14 new gene therapy programs, including two clinical programs in Batten disease, exceeding target of least one new clinical program in 2019. Target enrollment has been achieved in the Phase 1/2 study in CLN6 Batten disease, and the first patient has been dosed in the Phase 1/2 study in CLN3 Batten disease. • Maintained and strengthened the balance sheet. The current cash position of approximately $505 million (preliminary and unaudited) at December 31, 2018 is expected to fund ongoing operations into at least mid-2021. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, "During 2018 we advanced several steps closer to our 2023 vision to treat at least 5,000 patients and achieve $1 billion in global revenue. Following the new approvals for our Fabry precision medicine Galafold in the U.S. and Japan, and continued growth momentum in international markets, we have exceeded our 2018 guidance. Patients are also now being treated in multiple Amicus clinical studies, including our Phase 1/2 and pivotal studies of AT-GAA for Pompe disease, as well as Phase 1/2 studies of our investigational gene therapies for CLN3 and CLN6 Batten disease. Today we are in a stronger position than ever to become a leading global biotechnology company focused on transforming the lives of people living with these rare, life-threatening conditions and creating significant value for our shareholders." Amicus is focused on the following five key strategic priorities in 2019:
• Nearly double again annual revenue for Galafold (FY19 guidance of $160M-$180M in worldwide revenue) with 1,000+ Fabry patients on Galafold by year end • Complete enrollment in pivotal study in Pompe disease and report additional Phase 2 data • Report additional two-year results from Phase 1/2 clinical study in CLN6 Batten disease and complete enrollment in ongoing CLN-3 Batten disease Phase 1/2 study • Establish preclinical proof of concept for Fabry and Pompe gene therapies • Maintain a strong financial position Mr. Crowley will discuss Amicus' corporate objectives and key milestones in a presentation at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 8:30 a.m. PT (11:30 a.m. ET). A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days. Full-Year 2018 Financial Summary and 2019 Guidance Amicus recorded approximately $91 million (preliminary and unaudited) in full-year 2018 revenue from commercial sales and reimbursed expanded access programs for Galafold. For the full-year 2019 the Company anticipates total Galafold revenue of $160 million to $180 million. Prescription growth in 2018 was largely driven by EU and other countries outside the U.S. and Japan. Growth in 2019 is expected to be driven by continued growth in EU markets, further geographic expansion, and further success from the first full year of launch in the U.S. and Japan. Cash, cash equivalents, and marketable securities totaled just over $500 million (preliminary and unaudited) at December 31, 2018. The Company expects to end 2019 with approximately $300 million in cash on hand. The current cash position is anticipated to fund ongoing operations into at least mid- 2021. Program Highlights Galafold (Migalastat) Oral Precision Medicine for Fabry Disease Galafold is an oral precision medicine for Fabry disease approved in the EU and other geographies to treat Fabry disease in patients 16 years or older who have amenable genetic mutations. The U.S. FDA approved Galafold under Subpart H for the treatment of adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. An estimated 35% to 50% of the global Fabry population may be suitable for treatment with Galafold on the basis of their genetic mutations, or variants. For patients who are not suitable for treatment with Galafold on the basis of their genetic mutations, or variants, Amicus is advancing a next-generation gene therapy. Global Galafold Updates: • 650+ patients (naïve and ERT-switch) on reimbursed Galafold worldwide as of December 31, 2018. • Approvals secured in eight geographies including Australia, Canada, EU, Israel, Japan, South Korea, Switzerland, and United States and pending in Taiwan and several additional markets. • U.S. launch exceeded internal expectations with 149 new patient prescriptions, also known as patient referral forms (PRFs), as of December 31, 2018. Time to shipment was up to 60 days, limiting 2018 revenue impact but providing a strong foundation for 2019. • Pricing and reimbursement secured in 24 countries. • Registry and other Phase 4 supportive studies underway. AT-GAA for Pompe Disease AT-GAA is a novel treatment paradigm in Phase 3 development that consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose 6-phosphate (M6P), to enhance uptake, co-administered with AT2221, a pharmacological chaperone. Positive results from a global Phase 1/2 clinical study (ATB200-02) have shown consistent and durable responses across key measures of safety, functional outcomes and biomarkers in both ERT-switch and ERT-naïve Pompe patients following up to 18 months of treatment with AT-GAA. The Company's strategy is to enhance the body of clinical data for AT-GAA in ongoing clinical studies, including the pivotal study (PROPEL, also referred to as ATB200-03) to deliver this potential new therapy to as many people living with Pompe disease as soon as possible. Based on regulatory feedback from both the U.S. FDA and European Medicines Agency (EMA), the PROPEL study is expected to support approval for a broad indication, including ERT-switch and treatment-naïve patients.
Pompe Program Updates: • 1000L scale material released for pivotal PROPEL study. • Dosing initiated in PROPEL study. • WuXi partnership strengthened with 5-year supply agreement. Anticipated Pompe Program Milestones in 2019: • New data from the Phase 1/2 ATB200-02 clinical study, including final 24-month data in Cohorts 1-3, and initial 6- month data in additional ERT-switch patients (Cohort 4). • Retrospective natural history study data in approximately 100 ERT-treated Pompe patients. • Additional supportive studies, including an open-label study in pediatric patients. • Full enrollment in Phase 3 PROPEL study. • Advance agreed upon CMC requirements to support BLA. Gene Therapy Programs for Rare Metabolic Diseases During the third quarter and early fourth quarter of 2018, Amicus expanded its pipeline and future growth platform [link here] to include 14 new gene therapy programs and future growth platform for rare metabolic diseases, including 10 preclinical and clinical stage adeno associated virus 9 (AAV9) programs (intrathecal delivery) for neurologic lysosomal storage disorders (LSDs). Together these 10 programs have the potential to address 10,000+ people living with these neurologic LSDs and represent a $1 billion recurring revenue opportunity. Amicus is also developing four next-generation AAV gene therapies for Fabry disease, Pompe disease, CDKL5 deficiency disorder (CDD) and one additional undisclosed rare metabolic disorder. In Batten disease, compelling proof of concept has been demonstrated in preclinical studies in CLN6, CLN3, and CLN8, as well as initial clinical safety and efficacy in a Phase 1/2 study in patients with CLN6. The Company has also shown early proof of principle for Amicus DNA constructs for optimized gene therapies for Fabry and Pompe diseases. Gene Therapy Program Updates: • First patient treated in CLN3 Batten disease Phase 1/2 study with no serious adverse events reported to date. • Target enrollment achieved in CLN6 Batten disease Phase 1/2 study, with 12 patients receiving a single administration of gene therapy (exposure ranging from ~1 to 34 months). Anticipated Gene Therapy Pipeline Milestones in 2019: • Additional two-year data from CLN6 Batten disease Phase 1/2 study. • Full enrollment of ongoing CLN3 Batten disease Phase 1/2 study. • Preclinical data for next-generation gene therapies for Fabry, Pompe and CDD. • Preclinical work across additional neurologic LSDs. About Galafold Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable GLA variants. In these patients, Galafold works by stabilizing the body's own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland and the U.S. U. S. INDICATIONS AND USAGE Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. U.S. IMPORTANT SAFETY INFORMATION ADVERSE REACTIONS The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.
USE IN SPECIFIC POPULATIONS There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition. Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis. The safety and effectiveness of Galafold have not been established in pediatric patients. To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf. EU Important Safety Information Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation. • Galafold is not intended for concomitant use with enzyme replacement therapy. • Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of Galafold in children 0–15 years of age have not yet been established. • No dosage adjustments are required in patients with hepatic impairment or in the elderly population. • There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse. • While taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk. • Contraindications to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION. • It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on Galafold or switched to Galafold. • OVERDOSE: General medical care is recommended in the case of Galafold overdose. • The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS. • Call your doctor for medical advice about side effects. For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com, and follow us on Twitter and LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including,
without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2017 as well as our Quarterly Report on Form 10-Q for the quarter September 30, 2018. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino, IRC Vice President, Investor Relations and Corporate Communications spellegrino@amicusrx.com (609) 662-5044 Media: Pure Communications Jennifer Paganelli jpaganelli@purecommunications.com (347) 658-8290 FOLD–G


QuickBooks Pro has the capability to be hosted on the cloud and therefore most of the people use the QuickBooks Pro hosting instead of installing it on their local desktop and then going through the various hassles of the traditional method of accounting.
In order to enhance the performance of the robust QuickBooks Pro hosting solution, you can use the following methods and capitalize on the benefits of both cloud platform and the effective software.
By using the latest version of any software, you get the very common benefits of improved features, minimized bugs, enhanced security and the same goes for QuickBooks Pro hosting with additional advantages of using the latest version.
The Intuit releases the latest version of the software every year and you should start using it as soon as it arrives in the market. The basic motive behind providing updates for a software is improvement and if you are getting an enhanced version of the software then you should not miss the chance to make the most from this beneficial opportunity.
Though QuickBooks Pro hosting is itself a very useful and effective software, still you can gain a lot by integrating it with different add-ons. These add-ons are available at a very cheap price and they offer better customization of your accounting software with many areas of improvements. But instead of stuffing your QB Pro with multiple add-ons, you should start using only those add-ons which are important and useful for your business.
Like the Tsheet add-on can be used for time tracking and better management of employees by keeping a track on their time and work both, but if your business doesn't need such system then you don't need to use it.
DOI is the latest trending topic on the social media, but it is not applicable while facing issues with your QuickBooks Pro hosting solution. Many people try to solve the IT issues of their cloud hosting service while avoiding the round the clock and free customer support service offered by their cloud providers. In such cases, you are wasting your precious time and not dealing with the issues professionally.
So it is always better to let the experts handle your issues because they know it better than you, especially in the case of technical issues.


The development of the European Union has been one of the most profound advances in European politics and society this century. Yet the institutions of Europe and the 'Eurocrats' who work in them have constantly attracted negative publicity, culminating in the mass resignation of the European Commissioners in March 1999. In this revealing study, Cris Shore scrutinises the process of European integration using the techniques of anthropology, and drawing on thought from across the social sciences. Using the findings of numerous interviews with EU employees, he reveals that there is not just a subculture of corruption within the institutions of Europe, but that their problems are largely a result of the way the EU itself is constituted and run. He argues that European integration has largely failed in bringing about anything but an ever-closer integration of the technical, political and financial elites of Europe - at the expense of its ordinary citizens. This critical anthropology of European integration is essential reading for anyone with an interest in the culture and politics of the EU.
Do political boundaries impact on concepts of language? How significant is language for citizenship in contemporary Europe? Can disputed languages acquire full status? Should non-European languages receive recognition from the EU? These are among the many questions explored in this new study of official, regional and disputed languages in an ever-changing European context. Broad policy issues and the performance of the range of instruments of policy at local, national and European levels are illustrated with reference to case studies across Europe.
How do political authorities build support for themselves and their rule? Doing so is key to accruing power, but it can be a complicated affair. The European Union, as a novel political entity, faces a particularly difficult set of challenges. The Politics of Everyday Europe argues that the legitimation of EU authority rests in part on a transformation in the symbols and practices of everyday life in Europe. The Single Market and the Euro, the legal category of European Citizen and policies promoting the free movement of people, EU public architecture, arts and popular entertainment, and EU diplomacy and foreign policy all generate symbols and practices that change peoples' day-to-day experiences naturalizing European governance.The modern nation-state has long used similar strategies of nationalism and 'imagined communities' to legitimize its political power. But the EU's cultural infrastructure is unique, as it navigates European national identities with a particularly banality, trying to make the EU seem complementary to, not in competition with, the nation-states. While this cultural legitimation has successfully underpinned the EU's surprising political development, Europe today is more often met with indifference by its citizens rather than affection. As economic and political crises have stretched European social solidarity to the breaking point, this book offers a clear theoretical framework for understanding how everyday culture matters fundamentally in the political life of the EU, and how the construction of meaning can be a potent power resource-albeit one open to contestation and subversion by the very citizens it calls into being.
"Castles and Davidson explore these important questions and issues in a wide-ranging and extremely engaging analysis that considers citizenship, difference and democracy both in theoretical and applied terms. Offering a truly international framework, they examine citizenship in both western countries and the Asia-Pacific region and draw on important and illuminating examples throughout to illustrate and extend their argument."--BOOK JACKET.
This book addresses key transformations in citizenship politics in the EU ,ember states. The contributors argue that the anti-discrimination agenda set out in the Treaty of Amsterdam has had an impact on traditional patterns of national integration of ethnic minorities and migrants in Europe. Comparing transformations in French and British politics of citizenship, the book focuses in particular upon the religious dimension of discrimination and Islam in Europe.
Exit, like entry, has helped define citizenship over the last two centuries, yet little attention has been given to the politics of emigration. How have countries impeded or facilitated people leaving? How have they perceived and regulated those who leave? What relations do they seek to maintain with their citizens abroad and why? Citizenship and Those Who Leave reverses the immigration perspective to examine how nations define themselves not just through entry but through exit as well.
'The volume provides a rich quarry of data and ideas on social policy and citizenship.' - Gerda Falkner, Political Studies '. . . this book is inspiring to read since it is full of insights and opens up many of the very central concepts of today's ideological debate about the condition of welfare states of Europe . . . the book can be recommended to students and scholars who want to go beyond the traditional analysis of the European welfare states.' - Lennart Nygren, European Journal of Social Work the Politics of Social Policy in Europe analyses and critically assesses tensions and uncertainties which are haunting social policy provision throughout Europe in the 1990s. the expansion in social expenditures associated with the 1950s and 1970s has been replaced by retrenchment and pessimism in the 1990s. Disillusion prevails throughout the community due to growing disparity between the objectives of policy statements and the real life experience of EU citizens.
The contributors to this study address the question of how political theory is relevant to the construction of new Europe and the tie-in issues of citizenship, social justice and political legitimacy. By using techniques of contemporary political theory, the book argues that the emergence of new Europe poses fundamental questions of value and principle and challenges more established political theories in the process.
This book recognises sexuality as a mainstream concept in political analysis and explores issues in the politics of sexuality that are highly salient and controversial today. These include conceptions of citizenship and nationality linked to gender and sexuality, the legislation about the age of consent, prostitution and 'trafficing in women', the international politics of population control, abortion, sexual harrassment, and sexuality in the military. The international team of contributors provide a wide range of perspectives in a variety of contexts. On a national level they offer illustrative case studies from the UK, Ireland, the Netherlands, Spain and Israel among others, and on an international plane they cover the European Union, the UN Conference on Population and Development and the role of the Vatican as international arbiter. Moreover, the volume addresses the interaction between political discourse and the work of major theorists such as Weber, Freud, Foucault, Irigaray and Butler.


text:
$('#dialogo_confirmar_borrado').on('show.bs.modal', function (event) {
    var button = $(event.relatedTarget);
    var etiqueta_medicion = button.data('etiqueta_medicion');
    var id_medicion = button.data('id_medicion');
    var id_entidad = button.data('id_entidad');
    var modal = $(this);
    var link = 'index.php?page=medicion_borrar&id_medicion=' + id_medicion + '&id_entidad=' + id_entidad;
    modal.find('#etiqueta_medicion').text(etiqueta_medicion);
    modal.find('#borrar').attr('href', link);
});

//Generación/creación de mediciones
$('#btn_confirm_generar').click(function (e) {
    e.preventDefault();
    var anyo = $('#anyo').val();
    if ($.isNumeric(anyo)
            && anyo >= $('#anyo').attr('min') && anyo <= $('#anyo').attr('max')) {
        var texto_generando = $(this).data('texto_generando');
        $('#form_generar').submit();
        $('#dialogo_confirmar_generar .modal-body').html("
 " + texto_generando + "
");
        $('#dialogo_confirmar_generar .modal-footer').hide();
    }
});

//Carga de mediciones
$('#btn_confirm_cargar').click(function (e) {
    e.preventDefault();
    var registros = $('#registros').val();
    if ($.isNumeric(registros)
            && registros >= 1 && registros <= $('#registros').attr('max')) {
        var texto_cargando = $(this).data('texto_cargando');
        $('#form_cargar').submit();
        $('#dialogo_confirmar_cargar .modal-body').html("
 " + texto_cargando + "
");
        $('#dialogo_confirmar_cargar .modal-footer').hide();
    }
});

//Tablas de valores
$('.tabla_valores').DataTable({
    "bPaginate": false,
    "bSort": false,
    scrollY: "400px",
    scrollX: true,
    scrollCollapse: true,
    paging: false,
    fixedColumns: true,
    dom: "<'row'<'col-sm-12'B>>" +
            "<'row'<'col-sm-12'tr>>" +
            "<'row'<'col-sm-12'>>",
    buttons: [
        {
            extend: 'collection',
            text: " ",
            buttons: [
                {extend: 'csv', text: " Exportar a CSV"},
                {extend: 'excel', text: " Exportar a Excel"},
                {extend: 'print', text: " Imprimir/PDF"}
            ]
        }
    ]
});

//Barra de botones
$(document).ready(function () {
    var botones = $('#botones').html();
    $('#tabla_mediciones_filter').append(botones);
});

redpajama_set_name: RedPajamaGithub


text:
Q: Reference an Authorizer definition in an API Gateway path I've defined a custom authorizer in my cloudformation template:
MyCustomAuthorizer:
  Type: AWS::ApiGateway::Authorizer
  Properties:
    Name: "MyCustomAuthorizer"
    Type: "TOKEN"
    AuthorizerUri: "arn:my_lambda"
    IdentitySource: "method.request.header.Auth"
    RestApiId:
      Ref: ApiGatewayApi

And I have a Api Gateway API:
  ApiGatewayApi:
    Type: AWS::ApiGateway::RestApi
    Properties:
      Name: "ApiGatewayApi"
      Description: "Api gateway REST API"
      Body:
        basePath: "/prod"
        schemes:
        - "https"
        paths:
          /echo:
            get:
              consumes:
              - "application/json"
              produces:
              - "application/json"
              responses:
                "200":
                  description: "200 response"
                  schema:
                    $ref: "#/definitions/schema"
              security:
                - sigv4: []

How do I make specifically the /echo path use MyCustomAuthorizer?
I can do this on the console using the instructions here

A: The documentation has an example. You need to add the custom authorizer in the 'security' property within the method
  "securityDefinitions" : {
    "test-authorizer" : {
      "type" : "apiKey",                         // Required and the value must be "apiKey" for an API Gateway API.
      "name" : "Authorization",                  // The source header name identifying this authorizer.
      "in" : "header",                           // Required and the value must be "header" for an AAPI Gateway API.
      "x-amazon-apigateway-authtype" : "oauth2", // Specifies the authorization mechanism for the client.
      "x-amazon-apigateway-authorizer" : {       // An API Gateway custom authorizer definition
        "type" : "token",                        // Required property and the value must "token"
        "authorizerUri" : "arn:aws:apigateway:us-east-1:lambda:path/2015-03-31/functions/arn:aws:lambda:us-east-1:account-id:function:function-name/invocations",
        "authorizerCredentials" : "arn:aws:iam::account-id:role",
        "identityValidationExpression" : "^x-[a-z]+",
        "authorizerResultTtlInSeconds" : 60
      }
    }
  }

   "/http" : {
  "get" : {
    "responses" : { },
    "security" : [ {
      "test-authorizer" : [ ]
    } ],
    "x-amazon-apigateway-integration" : {
      "type" : "http",
      "responses" : {
        "default" : {
          "statusCode" : "200"
        }
      },
      "httpMethod" : "GET",
      "uri" : "http://api.example.com"
    }
  }
}

redpajama_set_name: RedPajamaStackExchange


Why should you get cover?
We can arrange comprehensive insurance that will cover you, from the day you sign up, for playing, practicing, riding, or participating in sports in any way.
If the worst should happen, and you are unable to work due to illness or accidental injury, your income protection plan will pay you an income if unable to work. The amount of time the income will be paid will depend on the type of plan. Some of the more affordable plans will pay an income until your return to work, a maximum of 2 years; or end of the policy term. Other plans will keep paying out until you are able to return to work or until the end of plan term - whichever is sooner.
Your plan covers you from day one, and you can choose how long you have to be unwell before your plan begins paying.


Desired to the awesome blog, At this point that you are seeing Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) publish. You can find any kind of Alternative Pain Relief products that will perhaps you desire with in this case. We complete publish countless products that has a great good quality, which Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) can be a product that we recommend for your needs. You'll want to look into this page meticulously to achieve certain beneficial home elevators Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) before you decide to shop for the application.
The item account earlier may be account before you acquire Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3). Then if you're engaged to buy Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) that construction because of Biofreeze type, you can actually press Buy Link below. The following Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) containing object passcode: B00SGVKQEU.
Not necessarily not having rationale people highly recommend Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) for you, it can be all considering Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) is often a item containing so great quality by means of trustworthy Biofreeze brand. Moreover this Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) post, this approach world-wide-web at the same time gives other posts to suit your needs, and you could find it utilize the research compartment of which placed besides this site. You need to click the ACQUIRE BUTTON below if you happen to want to acquire the following Bio Freeze Cold Therapy Pain Relief 360 Degree Spray, 4 Ounce (Pack of 3) item.


Do you think that taking into account this bandwidth savings, those 12 ROPs would make more sense?
From everything I've seen so far, PowerVR5 Series was more ahead of the competition than PowerVR6 Series is right now. In fact Nvidia has already surpassed them, especially when you consider the full OpenGL 4.4 API support, and Adreno and Mali have become very competitive, too, and Mali T760 should also have around 380 Gflops of performance, along with hardware assisted global illumination.